<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473499</url>
  </required_header>
  <id_info>
    <org_study_id>BBM-VS54-HOM</org_study_id>
    <nct_id>NCT00473499</nct_id>
  </id_info>
  <brief_title>PEPCAD III Substudy: Stem Cell Mobilization</brief_title>
  <acronym>PEPCADIIIsub</acronym>
  <official_title>Paclitaxel-Eluting PTCA-Balloon in Combination With the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease - Substudy Homburg/Saar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the PEPCAD III substudy is to assess the efficacy of the Paclitaxel-eluting DEBlue&#xD;
      stent system in the treatment of stenoses in native coronary arteries compared to the&#xD;
      Sirolimus-eluting Cypher stent by intravascular ultrasound (IVUS) and to study the influence&#xD;
      of both devices on endothelial function, coronary flow reserve, and stem cell mobilization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the PEPCAD III substudy is to assess the efficacy of the DEBlue®&#xD;
      Paclitaxel-eluting stent system in the treatment of stenoses in native coronary arteries&#xD;
      compared to the Sirolimus-eluting Cypher stent by intravascular ultrasound (IVUS) and to&#xD;
      study the influence of both devices on endothelial function, coronary flow reserve, and stem&#xD;
      cell mobilization. This study is a prospective, randomized, single-center, two-armed phase-II&#xD;
      study. During the PEPCAD III trial, 40 patients of the Homburg / Saar center will be randomly&#xD;
      assigned to ei-ther one of the treatment groups (20 patients treated with DEBlue, 20 patients&#xD;
      with Cypher®). Patients with stable or selected forms of unstable angina or documented&#xD;
      ischemia due to a significant lesion in a native coronary artery will be included. Vessels&#xD;
      may not supply an en-tirely infarcted myocardial area. Additional 20 patients receiving&#xD;
      uncoated stents (Coroflex® Blue, B.Braun) will undergo the same diagnostic procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stem cell mobilization and differentiation</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>endothelial function</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>late lumen loss</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>DEBlue stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel coated balloon with CoCr stent mounted on it</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Coroflex Blue stent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEBlue vs Cypher vs BMS</intervention_name>
    <description>BMS vs DES vs DEB+BMS</description>
    <arm_group_label>Coroflex Blue stent</arm_group_label>
    <arm_group_label>Cypher stent</arm_group_label>
    <arm_group_label>DEBlue stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stable or unstable angina or documented ischemia due to a significant&#xD;
             lesion in a native coronary artery&#xD;
&#xD;
          -  Patients eligible for coronary revascularization by means of PCI&#xD;
&#xD;
          -  Intention to treat one lesion with one stent&#xD;
&#xD;
          -  Patients suitable for coronary revascularization of any sort (balloon angioplasty,&#xD;
             device-assisted balloon-angioplasty, or coronary artery bypass grafting)&#xD;
&#xD;
          -  Patients must be ≥ 18 years of age&#xD;
&#xD;
          -  Women of childbearing potential may not be pregnant nor have the desire to becoming&#xD;
             pregnant during the first year following the study procedure. Hence, patients will be&#xD;
             advised to use an adequate birth control method up to and including 9 months follow-up&#xD;
&#xD;
          -  Patients who are mentally and linguistically able to understand the aim of the study&#xD;
             and to show sufficient compliance in following the study protocol&#xD;
&#xD;
          -  Patients must agree to undergo the 9 months angiographic follow-up&#xD;
&#xD;
          -  Patients must agree to undergo the 1 and 3 year clinical follow-up&#xD;
&#xD;
          -  Patient is able to verbally acknowledge an understanding of the associated risks,&#xD;
             benefits, and treatment alternatives to therapeutic options of this trial, e.g.&#xD;
             balloon angioplasty by means of the Paclitaxel-eluting PTCA-balloon catheter in&#xD;
             combination with the Coroflex BlueTM stent or the Sirolimus-eluting CypherTM stent.&#xD;
             The patients, by providing informed consent, agree to these risks and benefits as&#xD;
             stated in the patient informed consent document.&#xD;
&#xD;
          -  Significant stenoses in native coronary arteries with nominal stent diameters between&#xD;
             ≥ 2.5 mm and ≤ 3.5 mm and &lt; 24 mm in length&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unprotected left main&#xD;
&#xD;
          -  In stent restenosis&#xD;
&#xD;
          -  Indication for more than one lesion to treat, even as staged procedure&#xD;
&#xD;
          -  Intended bifurcational stenting&#xD;
&#xD;
          -  Patients requiring chronic anticoagulation&#xD;
&#xD;
          -  SVG and AG&#xD;
&#xD;
          -  Acute MI (STEMI, NSTEMI)&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Chronic total occlusions&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with stand alone balloon angioplasty, or stent deployment 6 months prior to&#xD;
             enrolment into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes, Homburg/Saar, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg / Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Scheller B, Speck U, Böhm M. Prevention of restenosis: is angioplasty the answer? Heart. 2007 May;93(5):539-41.</citation>
    <PMID>17435062</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.</citation>
    <PMID>17101615</PMID>
  </reference>
  <reference>
    <citation>Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006 Aug;240(2):411-8.</citation>
    <PMID>16864669</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004 Aug 17;110(7):810-4. Epub 2004 Aug 9.</citation>
    <PMID>15302790</PMID>
  </reference>
  <reference>
    <citation>Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, Shimizu M, Komoda H, Node K. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation. 2007 Feb 6;115(5):553-61. Epub 2007 Jan 29.</citation>
    <PMID>17261663</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Bruno Scheller</name_title>
    <organization>University Hospital, Saarland</organization>
  </responsible_party>
  <keyword>drug eluting balloon</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

